A. Stoppa

M. Reynaud‐Gaubert, J. Gaubert, P. Fuentes, 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.

J. Bourhis, V. Leblond, G. Marit, 1995, Stem cells.

EFFICACY AND SAFETY OF RITUXIMAB IN B-CELL POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: RESULTS OF A PROSPECTIVE MULTICENTRE PHASE II STUDY Running head: Rituximab in PTLD

G. Salles, A. Fischer, É. Oksenhendler, 2017 .

Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution

R. Bouabdallah, L. Xerri, B. Chetaille, 2013, Leukemia & lymphoma.

phase 2 study lymphoproliferative disorders: results of a prospective multicenter Efficacy and safety of rituximab in B-cell post-transplantation

G. Salles, A. Fischer, É. Oksenhendler, 2011 .

A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

R. Bouabdallah, L. Xerri, B. Chetaille, 2006, Bone Marrow Transplantation.

Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery.

R. Bouabdallah, D. Blaise, P. Viens, 1996, Journal of hematotherapy.

High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation

R. Bouabdallah, D. Blaise, M. Mohty, 2000, Bone Marrow Transplantation.

Monoclonal antibodies and cytomegalovirus infections

R. Bouabdallah, D. Coso, G. Damaj, 2004, European journal of haematology.

Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma.

J. Rey, I. Poizot-Martin, R. Costello, 2003, AIDS.

Autoimmune polyendocrine failure — Type 1 (insulin-dependent) diabetes mellitus and hypothyroidism — after allogenic bone marrow transplantation in a patient with lymphoblastic leukaemia

F. Birg, C. Thivolet, B. Vialettes, 1993, Diabetologia.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

P. Richardson, H. van de Velde, A. Di Bacco, 2017, Haematologica.

A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.

J. Reiffers, P. Berthaud, P. Hurteloup, 1996, Leukemia.

A Randomized Trial of Hydroxyurea Versus VP 16 in Adult Chronic Myelomonocytic Leukemia

B. Pégourié, G. Mufti, D. Oscier, 2022 .

Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.

E. Solary, H. Tilly, E. Wattel, 1999, Advances in experimental medicine and biology.

Autologous stem cell transplantation versus chemotherapy for adult patients with acute myeloid leukemia in first remission: the BGMT Group experience.

P. Cony-Makhoul, D. Blaise, J. Reiffers, 1993, Nouvelle revue francaise d'hematologie.

Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation.

D. Olive, D. Blaise, P. Viens, 1990, Blood.

195 Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS)

A. Stamatoullas, E. Solary, P. Fenaux, 1997 .

Intensive Therapy of Myelodysplastic Syndromes and Secondary Leukemias: Preliminary Findings of the French Experience

E. Solary, H. Tilly, E. Wattel, 1997 .

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

B. Pégourié, O. Decaux, M. Mohty, 2016, Blood.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2016, Blood.

Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014

N. Jourde-Chiche, S. Burtey, P. Brunet, 2016, Blood Cancer Journal.

Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial

B. Pégourié, P. Richardson, P. Moreau, 2014 .

P. Moreau, M. Macro, X. Leleu, 2020, Leukemia & lymphoma.

(IFM) myeloma: a phase 2 study of the Intergroupe Francophone du Myélome autologous stem cell transplantation in patients with de novo multiple Bortezomib and high-dose melphalan as conditioning regimen before

B. Pégourié, J. Mary, P. Moreau, 2013 .

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

B. Pégourié, J. Mary, P. Moreau, 2010, Blood.

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

D. Blaise, M. Mohty, D. Coso, 2004, Bone Marrow Transplantation.

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

B. Pégourié, P. Moreau, X. Leleu, 2013, Leukemia.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

B. Pégourié, O. Decaux, C. Sebban, 2011, Blood.

Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2011 .

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

T. Willis, B. Pégourié, P. Richardson, 2018, Blood.

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

B. Pégourié, C. Sebban, P. Moreau, 2014, Leukemia.

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC

I. Yakoub-Agha, M. Mohty, H. Avet-Loiseau, 2018, Bone Marrow Transplantation.

myeloma autologous stem cell transplantation in newly diagnosed multiple thalidomide plus dexamethasone as induction treatment before Bortezomib plus dexamethasone versus reduced-dose bortezomib,

O. Decaux, C. Sebban, P. Moreau, 2012 .

Tolerance and Biological Activity of Bolus Administration of Increasing Doses of Glycosylated Recombinant Interleukin-2 (SR 29009) in Patients with Hematological Malignancy

D. Olive, D. Blaise, P. Viens, 1992 .

IN VIVO ADMINISTRATION OF RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR CORRECTS ACQUIRED NEUTROPHIL FUNCTION DEFICIENCY ASSOCIATION WITH CHRONIC GRAFT‐VERSUS‐HOST DISEASE

D. Blaise, P. Viens, D. Maraninchi, 1993, British journal of haematology.

Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD

D. Blaise, C. Chabannon, F. Viret, 1999, Bone Marrow Transplantation.

Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials).

H. Dombret, A. Vekhoff, S. Chevret, 2005 .

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

B. Pégourié, O. Decaux, P. Moreau, 2015, Blood.

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

B. Pégourié, O. Decaux, P. Moreau, 2013, Blood.

Treatment of Relapsed Acute Leukemias with Systemic Recombinant Interleukin 2 (RU 49637)

D. Olive, D. Blaise, P. Viens, 1992 .

Sequential Bolus Administration of rIL-2 (RU 49637) in Treatment of Advanced Solid Malignancies

D. Olive, J. Gabert, D. Blaise, 1990 .

Sweet's syndrome induced by granulocyte colony-stimulating factor in a woman with congenital neutropenia.

J. Grob, M. Richard, Y. Berland, 1996, Journal of the American Academy of Dermatology.

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

J. Laubach, P. Richardson, P. Hari, 2018, Leukemia.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

B. Pégourié, O. Decaux, P. Moreau, 2015, Annals of Hematology.

Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III–IV acute graft-versus-host disease

D. Olive, D. Blaise, J. Reiffers, 1991 .

Fractionated total body irradiation and allogeneic bone marrow transplantation for standard risk leukemia.

D. Blaise, D. Maraninchi, A. Stoppa, 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Results of fractionated TBI prior to bone marrow transplantation in standard risk leukaemia at Marseille.

D. Blaise, D. Maraninchi, A. Stoppa, 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Anti‐LFA1 monoclonal antibody (25.3) for treatment of steroid‐resistant grade III‐IV acute graft‐versus‐host disease

D. Olive, D. Blaise, J. Reiffers, 1991, Transplant international : official journal of the European Society for Organ Transplantation.

Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involvement.

R. Bouabdallah, D. Blaise, N. Vey, 1999, Hematology and cell therapy.

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.

H. Dombret, S. Chevret, M. Fey, 2000, Leukemia.

Pilot study of immunotherapy with interleukin-2 after autologous stem cell transplantation in advanced breast cancers.

D. Olive, D. Blaise, P. Viens, 2000, Anticancer research.

Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.

R. Bouabdallah, D. Olive, D. Blaise, 1997, European cytokine network.

Use of Recombinant Interleukin-2 (RU 49637) After Autologous Bone Marrow Transplantation in Patients with Hematological Disease: Phase I–II Study

D. Olive, D. Blaise, J. Reiffers, 1992 .

Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA

P. Sonneveld, M. Béné, P. Moreau, 2019, Clinical Lymphoma Myeloma and Leukemia.

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

O. Decaux, M. Mohty, P. Moreau, 2022, Haematologica.

Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02

B. Pégourié, A. Duhamel, P. Moreau, 2010 .

Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.

J. Bourhis, V. Leblond, G. Marit, 1995, Bone marrow transplantation.

Reversible rituximab-induced rectal Kaposi’s sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma

F. Bertucci, A. Monneur, A. Stoppa, 2018, Clinical Sarcoma Research.

Unbalanced translocation t(5;17) in an atypical acute promyelocytic leukemia

F. Birg, J. Gabert, L. Coignet, 1995, Genes, chromosomes & cancer.

Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma

R. Bouabdallah, B. Esterni, D. Blaise, 2013, Leukemia and Lymphoma.

Does more intensive treatment cure more patients with acute myeloid leukemia? The BGMT Group.

J. Reiffers, G. Marit, D. Maraninchi, 1991, Seminars in hematology.

Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

B. Pégourié, I. Yakoub-Agha, M. Mohty, 2012, European journal of haematology.

Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.

R. Bouabdallah, D. Olive, D. Blaise, 2005, Blood.

High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation

R. Bouabdallah, D. Blaise, M. Mohty, 2007, Bone Marrow Transplantation.

Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation.

D. Blaise, M. Mohty, P. Viens, 2010, Experimental hematology.

Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.

R. Bouabdallah, B. Esterni, D. Blaise, 2010, Experimental hematology.

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus on Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

R. Bouabdallah, D. Blaise, R. Devillier, 2012, Mediterranean journal of hematology and infectious diseases.

Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen

D. Olive, D. Blaise, M. Mohty, 2003, Leukemia.

Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

H. Dombret, A. Vekhoff, S. Chevret, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Hematopoietic growth factors].

D. Blaise, P. Viens, D. Maraninchi, 1993, Presse medicale.

Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase.

D. Coso, F. Barlesi, C. Chabannon, 2015, Virology.

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg‐negative and anti‐HBc antibodies‐positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer

R. Bouabdallah, D. Coso, C. Chabannon, 2010, Journal of viral hepatitis.

PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE BY MONOCLONAL ANTIBODY TO INTERLEUKIN-2 RECEPTOR

D. Blaise, D. Maraninchi, M. Attal, 1989, The Lancet.

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.

D. Blaise, M. Mohty, P. Viens, 2003, Blood.

The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma

P. Moreau, H. Avet-Loiseau, X. Leleu, 2013, Clinical Cancer Research.

Minor clone provides a reservoir for relapse in multiple myeloma

N. Munshi, O. Decaux, P. Moreau, 2013, Leukemia.

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

R. Bataille, B. Grosbois, I. Yakoub-Agha, 2007, Blood.

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group

H. Dombret, A. Vekhoff, S. Chevret, 2005, Leukemia.

Liquid culture and cryopreservation of marrow cells of leukaemic patients prior to autologous bone marrow transplantation

D. Blaise, D. Maraninchi, A. Stoppa, 1989, British journal of haematology.

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

J. Rossi, R. Bataille, N. Ifrah, 1996 .

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

A. Palumbo, A. Hui, P. Ganly, 2016, The New England journal of medicine.

Comparable outcomes between unrelated and related donors after reduced‐intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high‐risk multiple myeloma

R. Bouabdallah, D. Blaise, D. Coso, 2012, European journal of haematology.

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

R. Bouabdallah, D. Blaise, M. Mohty, 2008, Bone Marrow Transplantation.

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

N. Kröger, S. Iacobelli, C. Crawley, 2018, Haematologica.

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

J. Rossi, R. Bataille, N. Ifrah, 1996, The New England journal of medicine.

Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies.

D. Olive, P. Viens, J. Pasquier, 1993, Acta endocrinologica.

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.

H. Dombret, A. Vekhoff, E. Vellenga, 2008, Blood.

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia

H. Dombret, S. Chevret, M. Fey, 2000, Leukemia.

Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.

G. Marit, N. Dastugue, D. Leroux, 1995, Leukemia.

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.

V. Leblond, P. Quartier, C. Antoine, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Fractionated total body irradiation and bone marrow transplantation in acute lymphoblastic leukemia.

D. Blaise, D. Maraninchi, J. Lagrange, 1990, International journal of radiation oncology, biology, physics.

Phase I–II Study of Carboplatin with VP16 and Aracytin for Poor-Risk-Acute Leukemia

J. Rossi, D. Blaise, E. Jourdan, 1998 .

A tumour‐associated antigen expression in human haematological malignancies

D. Olive, P. Coulie, F. Brasseur, 1993, British journal of haematology.

Phase I-II trial of Seraspenide (AcSDKP): a supressor of myelopoiesis protects against chemotherapy myelotoxicity (version 10 february 1993)

A. Vekhoff, C. Chastang, D. Khayat, 1994 .

Anästhesie zur Sectio caesarea

H. Hecker, A. Stoppa, H. Adams, 2003, Der Anaesthesist.

Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.

J. Bourhis, H. Dombret, S. Chevret, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution.

R. Bouabdallah, D. Blaise, P. Viens, 1998, Leukemia & lymphoma.

[Anaesthesia for caesarean section. Comparison of two general anaesthetic regimens and spinal anaesthesia].

H. Hecker, A. Stoppa, H. Adams, 2003, Der Anaesthesist.

Constitutional balanced pericentric inversions of chromosomes X, 2, and 5 in myeloid malignancies.

D. Birnbaum, N. Philip, D. Blaise, 1998, Cancer genetics and cytogenetics.

In vivo stimulation of neutrophil function by lenograstim (glycosylated rHug‐CSF) in oncohematologic patients: Results of a phase I trial

D. Blaise, P. Viens, A. Yver, 1994, Stem cells.

Phase I study of in vivo lenograstim (rHuG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation.

D. Blaise, P. Viens, A. Yver, 1994, Bone Marrow Transplantation.

CD34(+) immunoselected cells for poor graft function following allogeneic BMT.

R. Bouabdallah, D. Blaise, M. Mohty, 2000, Cytotherapy.

Cost–effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation

D. Blaise, P. Viens, N. Vey, 2003, Leukemia.

Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients.

D. Olive, J. Gabert, D. Blaise, 1991, Bone marrow transplantation.

Partial chimerism after T-cell-depleted allogeneic bone marrow transplantation in leukemic HLA-matched patients: a cytogenetic documentation.

D. Blaise, D. Maraninchi, A. Stoppa, 1988, Blood.

Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation

D. Blaise, M. Mohty, P. Viens, 2004, Bone Marrow Transplantation.

Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs

B. Esterni, D. Blaise, M. Mohty, 2012, Bone Marrow Transplantation.

Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.

R. Bouabdallah, L. Xerri, D. Blaise, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.

D. Blaise, C. Oudin, C. Chabannon, 2012, Experimental hematology.

A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor

R. Bouabdallah, D. Blaise, D. Coso, 2014, American journal of hematology.

Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience

B. Bonnotte, F. Girodon, D. Bouscary, 2011, Haematologica.

CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

D. Olive, D. Blaise, M. Mohty, 2004, Experimental hematology.

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

P. Sonneveld, V. V. D. van der Velden, M. Mohty, 2021, Blood.

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM

O. Decaux, P. Moreau, H. Avet-Loiseau, 2021, Blood.

Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

M. Mohty, P. Moreau, H. Avet-Loiseau, 2021, Leukemia.

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

R. Greil, R. Hájek, B. Paiva, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution

R. Bouabdallah, D. Blaise, N. Vey, 2004, Bone Marrow Transplantation.

Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery.

R. Bouabdallah, P. Viens, N. Vey, 1994, Bone marrow transplantation.

J. Esteve, H. Dombret, P. Fenaux, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: absence of eradication of the PNH clone and dependence of response on cyclosporin A administration

C. Arnoulet, N. Vey, D. Sainty, 1996, British journal of haematology.

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

H. Dombret, S. Chevret, B. Quesnel, 2006, Leukemia.

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

R. Peto, F. Mandelli, R. Gray, 1998, British journal of haematology.

Prospective Study Comparing Idarubicin and Daunorubicin in Elderly Patients with Acute Myeloid Leukemia

P. Cony-Makhoul, J. Reiffers, P. Hurteloup, 1992 .

Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling

E. Devilard, F. Bertucci, C. Nguyen, 2004, Oncogene.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

B. Pégourié, O. Decaux, P. Moreau, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02

B. Pégourié, O. Decaux, P. Moreau, 2011 .

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

Jean-Michel Nguyen, Caroline Bodet-Milin, Kenneth Anderson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience

J. Miguel, J. Bourhis, H. Dombret, 2005, Leukemia.

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

O. Decaux, M. Mohty, P. Moreau, 2019, Blood.

Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)

B. Pégourié, O. Decaux, P. Moreau, 2013 .

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2006, Haematologica.

Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center

R. Bouabdallah, M. Mohty, G. Damaj, 2004, European journal of haematology.

Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.

R. Bouabdallah, D. Blaise, M. Mohty, 2008, Clinical lymphoma & myeloma.

Trisomy 11 in acute myeloid leukemia: ten cases.

C. Arnoulet, G. Marit, N. Dastugue, 1994, Leukemia.

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

R. Bouabdallah, D. Blaise, C. Oudin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies.

R. Bouabdallah, D. Blaise, N. Vey, 1996, Bone marrow transplantation.

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

D. Blaise, M. Mohty, D. Coso, 2005, Leukemia.

The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.

D. Olive, D. Blaise, J. Reiffers, 1997, Leukemia & lymphoma.

Interleukin‐2 in Association with Increasing Doses of Interferon‐Gamma in Patients with Advanced Cancer

D. Olive, D. Blaise, C. Bressac, 1992, Journal of immunotherapy.

IL2 in Acute Leukemia

R. Bouabdallah, D. Blaise, J. Reiffers, 1996 .

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the french registry on autologous transplantation in multiple myeloma

R. Bataille, J. Bourhis, X. Troussard, 1995, Blood.

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

R. Bouabdallah, D. Olive, D. Blaise, 1998, Leukemia & lymphoma.

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs

O. Decaux, A. Lamblin, P. Moreau, 2013, Thrombosis and Haemostasis.

Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission

R. Bouabdallah, D. Blaise, M. Mohty, 2006, Bone Marrow Transplantation.

Efficacy and safety of Rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): Preliminary results of a multicenter, open label, phase II trial (M39037 TRIAL)

G. Salles, É. Oksenhendler, A. Moreau, 2002 .

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

B. Pégourié, P. Moreau, X. Leleu, 2014, Journal of Cancer.

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.

B. Pégourié, G. Mufti, D. Oscier, 1996, Blood.

Hevylite® to Monitor Response to Therapy in Multiple Myeloma

B. Pégourié, O. Decaux, P. Moreau, 2014 .

Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.

J. Rossi, R. Bouabdallah, D. Blaise, 2000, European cytokine network.

The benefit of induction chemotherapy in patients age ≥ 75 years

R. Bouabdallah, D. Blaise, V. Bardou, 2004, Cancer.

Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?

R. Bouabdallah, D. Blaise, M. Mohty, 2012, Leukemia & lymphoma.

Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors

B. Esterni, D. Blaise, D. Coso, 2014, Bone Marrow Transplantation.

Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice

M. Dimopoulos, A. Belch, E. Katodritou, 2018, European journal of haematology.

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial

O. Decaux, H. Nahi, S. Basu, 2017, Leukemia.

Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study

M. Labopin, D. Blaise, M. Mohty, 2016, Haematologica.

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

R. Greil, R. Hájek, B. Paiva, 2015, British journal of haematology.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

B. Pégourié, P. Cony-Makhoul, O. Decaux, 2015, Haematologica.

Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center.

R. Bouabdallah, L. Xerri, D. Blaise, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol).

J. Reiffers, G. Marit, D. Maraninchi, 1990, Nouvelle revue francaise d'hematologie.

Is there a place for blood stem-cell transplantation for the younger adult patient with acute myelogenous leukemia? BGMT Group.

J. Reiffers, M. Attal, A. Stoppa, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

P. Sonneveld, P. Moreau, T. Facon, 2021, Haematologica.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

M. Vekemans, P. Moreau, H. Avet-Loiseau, 2022, Blood.

Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): Long Term Results of a “Donor” Versus “No Donor” Comparison.

D. Blaise, M. Mohty, D. Coso, 2007 .

A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients.

S. Chevret, P. Morel, M. Macro, 2020, Blood.

Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission.

R. Bouabdallah, D. Blaise, D. Cowen, 1994, Bone marrow transplantation.

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

B. Pégourié, C. Sebban, P. Moreau, 2014, Haematologica.

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

M. Mohty, P. Moreau, F. Magrangeas, 2015, Blood.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

N. Munshi, M. Mohty, P. Moreau, 2015, Blood.

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

M. Mohty, H. Avet-Loiseau, M. Macro, 2020, Haematologica.

Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma.

R. Bouabdallah, D. Blaise, M. Mohty, 2011, Hematology/oncology and stem cell therapy.

Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Salvage Treatment for Relapsing Multiple Myeloma (MM): A “Donor” vs. “No Donor” Comparison.

R. Bouabdallah, D. Blaise, M. Mohty, 2006 .

Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT

R. Bouabdallah, B. Esterni, D. Blaise, 2011, Bone Marrow Transplantation.

Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide

D. Olive, D. Blaise, M. Mohty, 2002, Journal of leukocyte biology.

A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

P. Morel, M. Macro, L. Frenzel, 2017 .

New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias.

D. Birnbaum, S. Olschwang, A. Murati, 2007, Haematologica.

1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

B. Pégourié, C. Sebban, P. Moreau, 2012 .

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

A. Santoro, D. Rasco, R. Chopra, 2014 .

Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma

R. Bouabdallah, B. Chetaille, B. Esterni, 2014, Leukemia & lymphoma.

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice

M. Dimopoulos, A. Belch, E. Katodritou, 2018, Health science reports.

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

P. Ganly, J. Laubach, P. Richardson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study

I. Yakoub-Agha, E. Deconinck, M. Itälä-Remes, 2023, European journal of haematology.

EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE.

P. Morel, H. Avet-Loiseau, X. Leleu, 2021, Blood.

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Preliminary Results of an IFM Phase II Study

J. Harousseau, V. Coiteux, M. Attal, 2005 .

A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone

M. Mohty, J. Mary, P. Moreau, 2017 .

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

B. Pégourié, P. Moreau, M. Macro, 2017 .

Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.

D. Blaise, P. Viens, A. Iliadis, 1992, British Journal of Cancer.

CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma

J. Sancho, A. Santoro, D. Rasco, 2015 .

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

B. Pégourié, O. Decaux, P. Moreau, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma

P. Moreau, M. Macro, X. Leleu, 2023, British Journal of Haematology.

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

P. Moreau, G. Marit, G. Damaj, 2012, Leukemia & lymphoma.

High Relapse Rate of Acute Myeloid Leukemia with Translocation (8;21) or Inversion (16) in Elderly Patients Treated with Conventional Chemotherapy.

D. Coso, N. Vey, M. Mozziconacci, 2007 .

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study.

O. Decaux, P. Moreau, H. Avet-Loiseau, 2023, Haematologica.

Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02).

S. Leyvraz, P. Moreau, H. Avet-Loiseau, 2009 .

Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.

P. Richardson, P. Moreau, Jianchang Lin, 2016 .

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

A. Palumbo, A. Hui, P. Ganly, 2015 .

Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies

J. Rossi, D. Blaise, P. Weiller, 2004, Cancer Chemotherapy and Pharmacology.

Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2010 .

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

O. Decaux, M. Mohty, P. Moreau, 2022, Haematologica.

Autologous bone marrow transplantation for B cell malignancies after in vitro purging with floating immunobeads.

D. Blaise, P. Viens, D. Maraninchi, 1990, Bone marrow transplantation.

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

S. Iacobelli, P. Chevallier, I. Yakoub-Agha, 2023, Bone Marrow Transplantation.

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

X. Leleu, K. Laribi, V. Richez, 2023, Annals of Hematology.

Mycosis fungoides and allogenic bone marrow transplantation.

D. Blaise, D. Maraninchi, L. Coulier, 1994, Acta dermato-venereologica.

Heterogeneity of Rearranged T-Cell Receptor V-α and V-β Transcripts in Tumor-infiltrating Lymphocytes from Hodgkin’s Disease and Non-Hodgkin’s Lymphoma

R. Bouabdallah, F. Birg, L. Xerri, 1994 .

The Role of Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML): A Donor vs. No Donor Comparison.

D. Blaise, M. Mohty, D. Coso, 2004 .

PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

P. Sonneveld, P. Moreau, T. Facon, 2019, HemaSphere.

Cell surface expression of ICAM-1 (CD54) and LFA-3 (CD58), two adhesion molecules, is up-regulated on bone marrow leukemic blasts after in vivo administration of high-dose recombinant interleukin-2.

D. Olive, D. Blaise, P. Viens, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patients.

D. Olive, D. Blaise, P. Viens, 1999, Journal of immunotherapy.

Modifications of leukemic blast cells induced by in vivo high-dose recombinant interleukin-2.

D. Olive, D. Blaise, H. Chambost, 1994, Leukemia.

Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2015 .

Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group.

D. Blaise, X. Troussard, G. Marit, 1995, Blood.

Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000).

H. Dombret, A. Stamatoullas, A. Vekhoff, 2004 .

Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.

D. Olive, J. Gabert, D. Blaise, 1991, European Cytokine Network.

Rituximab–lenalidomide–dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma

R. Bouabdallah, B. Chetaille, D. Blaise, 2010, Leukemia & lymphoma.

Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

N. Texier, M. Macro, X. Leleu, 2020 .

INTENSIVE INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTS

J. Reiffers, P. Hurteloup, A. Stoppa, 1992 .